Last Updated: November 8, 2026

PROSTIN F2 ALPHA Drug Patent Profile

Name: PROSTIN F2 ALPHA Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Prostin F2 Alpha patents expire, and when can generic versions of Prostin F2 Alpha launch?

Prostin F2 Alpha is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in PROSTIN F2 ALPHA is dinoprost tromethamine. There is one drug master file entry for this compound. Additional details are available on the dinoprost tromethamine profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for PROSTIN F2 ALPHA?
What are the global sales for PROSTIN F2 ALPHA?
What is Average Wholesale Price for PROSTIN F2 ALPHA?

Summary for PROSTIN F2 ALPHA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	12
Patent Applications:	529
DailyMed Link:	PROSTIN F2 ALPHA at DailyMed

Drug patent expirations by year for PROSTIN F2 ALPHA

Recent Clinical Trials for PROSTIN F2 ALPHA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Centre Maribor	Phase 4
Aswan University Hospital	N/A
National University, Singapore	N/A

See all PROSTIN F2 ALPHA clinical trials

US Patents and Regulatory Information for PROSTIN F2 ALPHA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for PROSTIN F2 ALPHA

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982	3,657,327	⤷ Start Trial
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982	3,778,506	⤷ Start Trial
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982	3,706,789	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for PROSTIN F2 ALPHA

See the table below for patents covering PROSTIN F2 ALPHA around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Belgium	767926		⤷ Start Trial
Switzerland	563329		⤷ Start Trial
Switzerland	563330		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.